BioNTech's reported revenue has swung from $1.5B in 2025Q3 to $105.6M in 2026Q2 before rebounding to $1.3B in 2026Q3, suggesting earnings are driven by milestone and profit-share timing rather than steady commercial demand.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue and margins are highly volatile, with gross margin swinging from 8.1% in 2026Q2 to 92.0% in 2026Q3 and operating margin ranging from -192.1% to 9.7%, suggesting profitability depends heavily on the timing of partner-driven revenue against fixed R&D spend of $551.0M to $748.1M per quarter.
BioNTech is a leader in mRNA technologies, notably for co-developing the first approved mRNA COVID-19 vaccine with Pfizer.
The company is expected to outline focus areas and near- to longer-term milestones at the 44th Annual J.P. Morgan Healthcare Conference.
There is a bullish thesis on BioNTech SE highlighted by research platforms and value investing communities.
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 3, 2026 | $0.83+9.2% vs $0.76 | $1.5B+24.8% vs $1.2B |
Q3 2026 Aug 4, 2026 | -$3.70-54.3% vs -$2.40 | $121M-33.1% vs $180M |
Q2 2026 May 5, 2026 | -$2.43+4.4% vs -$2.54 | $136M-34.2% vs $207M |
Q2 2026 Mar 10, 2026 | -$1.44-556.7% vs -$0.22 | $1.1B+18.1% vs $902M |
A quarter that produced a surprise profit and a bigger 2026 forecast is sending Moderna (NASDAQ:MRNA | MRNA Price Prediction) higher again. Moderna stock is at $254.07 in morning trading, up 5%.
Axsome Therapeutics is generating rapid revenue growth from its expanding portfolio of central nervous system treatments. BioNTech maintains a massive cash position and virtually no debt while shifting its focus toward oncology and mRNA innovation.
BioNTech is rated Hold due to a narrowing pipeline, negative cash flow, and reliance on two main assets: pumitamig and gotistobart. Q3 profit is less meaningful than the widening gap between reported earnings and cash economics, with liquid assets declining despite reported net income. BNTX's revised revenue outlook reflects only a modest improvement, and ongoing cash burn, portfolio retrenchment, and pipeline concentration heighten risk.
BioNTech SE ( BNTX ) Q3 2026 Earnings Call November 3, 2026 8:00 AM EST Company Participants Douglas Maffei - Vice President of Strategy & Investor Relations Ugur Sahin - Co-Founder, CEO & Chair of the Management Board Özlem Türeci - Co-Founder, Chief Medical Officer & Member of Management Board Ramón Zapata-Gomez - CFO & Member of Management Board Annemarie Hanekamp - Chief Commercial Officer & Member of Management Board Conference Call Participants Akash Tewari - Jefferies LLC, Research Division Mohit Bansal - Wells Fargo Securities, LLC, Research Division Daina Graybosch - Leerink Partners LLC, Research Division Tazeen Ahmad - BofA Securities, Research Division Xiaochuan Dai - UBS Investment Bank, Research Division Asad Haider - Goldman Sachs Group, Inc., Research Division Jessica Fye - JPMorgan Chase & Co, Research Division Cory Kasimov - Evercore Inc. Terence Flynn - Morgan Stanley, Research Division Simon Baker - Rothschild & Co Redburn, Research Division Presentation Operator Welcome to BioNTech's Third Quarter 2026 Earnings Call. I will now hand the call over to Doug Maffei, Vice President of Investor Relations.
Benchmark BNTX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for BioNTech SE (BNTX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $87.51 | $21.98B | -13.43 | 0.2% | -61.28% | -8.06% | — | |
| $254.19 | $100.86B | -39.19 | -39.23% | -110.46% | -37.62% | — | |
| $29.39 | $167.51B | 41.91 | -1.65% | 6.34% | 4.58% | 5.85% | |
| $10.78 | $1.77B | -23.17 | 64.69% | -18.64% | — | — | |
| $10.35 | $294.18M | -3.77 | -51.43% | -312.88% | -41.86% | — | |
| $904.35 | $93.17B | 19.82 | 0.99% | 28.51% | 15.07% | 0.38% |
BioNTech SE (BNTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when BNTX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BioNTech SE (BNTX) stock FAQ — growth, dividends, profitability & financials explained
BioNTech SE (BNTX) reported $2.41B in revenue over the trailing twelve months. Revenue was $2.76B in fiscal year 2025. That is 4375% more than the $61.6M of fiscal year 2017.
BioNTech SE (BNTX) revenue fell by 23.4% over the trailing twelve months, compared with the twelve months before.
No. BioNTech SE (BNTX) reported a net loss of $1.48B over the trailing twelve months.
BioNTech SE (BNTX) had a return on equity (ROE) of -8.1% over the trailing twelve months. A negative ROE means the company lost money over the period.
BioNTech SE (BNTX) had negative free cash flow of $456.2M over the trailing twelve months.
